Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Claudia Url"'
Autor:
Eduard Schulz, Isabel Hodl, Patrick Forstner, Stefan Hatzl, Nazanin Sareban, Martina Moritz, Johannes Fessler, Barbara Dreo, Barbara Uhl, Claudia Url, Andrea J. Grisold, Michael Khalil, Barbara Kleinhappl, Christian Enzinger, Martin H. Stradner, Hildegard T. Greinix, Peter Schlenke, Ivo Steinmetz
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering fr
Externí odkaz:
https://doaj.org/article/d95143a5e2e14deebe59299291a8d7cc
Autor:
Hildegard Greinix, Barbara Dreo, Johannes Fessler, Patrick Forstner, Andrea J. Grisold, Nazanin Sareban, Peter Schlenke, Ivo Steinmetz, Barbara Kleinhappl, Christian Enzinger, Claudia Url, Stefan Hatzl, Isabel Hodl, Martina Moritz, Eduard Schulz, Michael Khalil, Barbara Uhl, Martin H Stradner
ObjectivesImmunocompromised patients are at risk of severe coronavirus disease 2019 and are considered a high priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Humoral vaccination response is impaired in these pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bca6dfbcd887c7a2d9746d5356b91ca7
https://doi.org/10.1101/2021.08.11.21261898
https://doi.org/10.1101/2021.08.11.21261898
Autor:
Nicole A. Hofmann, Sylvia Joussen, Wolfgang Wagner, Anna Ortner, Dirk Strunk, Claudia Url, Katharina Schallmoser, Nathalie Etchart
Publikováno v:
Bone Marrow Transplantation. 47:S88-S456
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d99681721f136359cab74815a145fd76
https://doi.org/10.1038/bmt.2012.37
https://doi.org/10.1038/bmt.2012.37
Autor:
Nathalie Etchart, Sylvia Joussen, Nicole A. Hofmann, Katharina Schallmoser, Dirk Strunk, Claudia Url, Andreas Reinisch, Wolfgang Wagner, Anna Ortner
Publikováno v:
Blood. 120:1916-1916
Abstract 1916 Clinical trials are underway to test the safety and efficacy of mesenchymal stem/progenitor cells (MSPCs) in various diseases. Due to their low frequency in situ, MSPC expansion is the prerequisite for dose finding studies as well as fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a44e2d8c16eb7289a0c150e262cd6304
https://doi.org/10.1182/blood.v120.21.1916.1916
https://doi.org/10.1182/blood.v120.21.1916.1916
Autor:
Katharina Schallmoser, Rokhsareh Rohban, Nathalie Etchart, Dirk Strunk, Anna Ortner, Claudia Url, Margareta Frühwirth, Andreas Reinisch, Christine Beham-Schmid
Publikováno v:
Blood. 118:1322-1322
Abstract 1322 Introduction. Mesenchymal Stem/Progenitor Cells (MSPC) are regarded as the universal skeletal progenitor, theoretically capable of differentiating into cartilage, bone, tendon and muscle. Their functions as pericytes as well as key bone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::695ef2e17d47ab4ca591b544882ea0a3
https://doi.org/10.1182/blood.v118.21.1322.1322
https://doi.org/10.1182/blood.v118.21.1322.1322